NewYork-Presbyterian/Weill Cornell Medical Center
428 E. 72nd Street, Suite 300 • New York, NY 10021
The Myeloma Center at New York Presbyterian – Weill Cornell Medical Center is a comprehensive program for the treatment of multiple myeloma and related plasma cell diseases. Our focus is on providing cutting edge medical technologies and the latest in myeloma treatment personalized to each patient.
In addition to experienced use of well-established effective treatments, we offer new therapies in the context of clinical trials for myeloma and related blood disorders.
Patients at the Myeloma Center have access to the newest therapies for plasma cell disorders through enrollment onto clinical trials. New clinical trials are now under continuing enrollment under the care of your treating physician. The myeloma center has access to both pharmaceutical industry and physician investigator initiated clinical trials as part of a world-class clinical research program.
learn moreIn addition to clinical research, Weill Cornell Medical College has an active basic science laboratory-based research program in myeloma where new targets for drug therapy and disease control can be discovered. Innovations in the laboratory can then be used in an active bench-to-clinic translational research context, this offering patients in need the latest in personalized drug therapies.
learn moreMyeloma is a cancer of a type of white blood cell called the plasma cell. It is the job of the plasma cell to produce immunoglobulins, proteins which serve in an integral role in immune system protection. An abnormal proliferation of one type (or clone) or plasma cell can lead to a spectrum of blood disorders including MGUS (monoclonal gammopathy of undetermined significance), multiple myeloma, amyloidosis, light chain deposition disease, amongst others.
learn more